Lineage Cell Therapeutics, Inc.
LCTX
$1.11
$0.032.78%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 104.86% | -16.26% | 126.00% | -881.58% | -428.89% |
| Total Depreciation and Amortization | 9.36% | 14.63% | 23.18% | 26.24% | 20.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -131.53% | -107.78% | -2,797.58% | 3,269.19% | 1,648.77% |
| Change in Net Operating Assets | 84.44% | -690.30% | 102.75% | 57.62% | -112.27% |
| Cash from Operations | -30.78% | -65.33% | 23.13% | 37.52% | -7.01% |
| Capital Expenditure | -671.43% | 43.30% | -9.32% | 89.29% | 72.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -213.55% | -597.83% | -100.00% | 100.00% |
| Cash from Investing | 28,385.71% | -222.23% | -681.94% | -100.31% | 99.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 35.71% | 0.00% | -7.14% | -23.08% | 0.00% |
| Issuance of Common Stock | -- | 6.00% | -6.95% | 20,720.00% | -- |
| Repurchase of Common Stock | 100.00% | -166.67% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 1,554.72% | 10.25% | -6.23% | 61,233.33% | -392.38% |
| Foreign Exchange rate Adjustments | -11.60% | 93.15% | 620.00% | -110.53% | 432.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 125.88% | -343.86% | -98.08% | 3.54% | 60.10% |